Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phenylketonuria revisited

J W Gerrard1

  • 1Department of Paediatrics, University of Saskatchewan, Saskatoon.

Clinical and Investigative Medicine. Medecine Clinique Et Experimentale
|October 1, 1994
PubMed
Summary
This summary is machine-generated.

Researchers developed a low-phenylalanine diet to treat the first child diagnosed with phenylketonuria (PKU). Despite initial skepticism, the dietary intervention showed biochemical improvements, marking a milestone in PKU management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of common infant feeding problems.

Canadian family physician Medecin de famille canadien·2010
Same author

Nocturnal enuresis.

Canadian Medical Association journal·2010
Same author

Nocturnal enuresis.

Canadian Medical Association journal·2010
Same author

Haemolytic Disease of the Newborn.

Canadian Medical Association journal·2010
Same author

The Pine House (Saskatchewan) Nutrition Project. II.

Canadian Medical Association journal·2010
Same author

Peroral Jejunal Biopsy.

Canadian Medical Association journal·2010
Same journal

Newsletter Spring 2026: Clinician Investigator Trainee Association of Canada (CITAC).

Clinical and investigative medicine. Medecine clinique et experimentale·2026
Same journal

A study of suicide risk and prognostic characteristics in patients with osteosarcoma.

Clinical and investigative medicine. Medecine clinique et experimentale·2026
Same journal

The expression and mechanism of action of MicroRNA-210 in preeclampsia.

Clinical and investigative medicine. Medecine clinique et experimentale·2026
Same journal

Risk assessment of intra-operative hemodynamic instability in patients with pheochromocytoma.

Clinical and investigative medicine. Medecine clinique et experimentale·2026
Same journal

Development and validation of a deep vein thrombosis risk nomogram for post-operative complications in prostate cancer patients.

Clinical and investigative medicine. Medecine clinique et experimentale·2026
Same journal

Analysis of the impact of SARS-CoV-2 infection on immune function and metabolic changes in college students.

Clinical and investigative medicine. Medecine clinique et experimentale·2026
See all related articles

Area of Science:

  • Biochemistry
  • Pediatrics
  • Metabolic Disorders

Background:

  • Phenylketonuria (PKU) is a rare genetic disorder requiring dietary management.
  • Early research focused on developing low-phenylalanine formulas for PKU treatment.
  • The case involved the first child treated with a phenylalanine-restricted diet.

Discussion:

  • The study details the contributions of Bickel, Hickmans, Gerrard, and Woolf in formula preparation and patient treatment.
  • The child, diagnosed at two years old with existing intellectual disability, received a phenylalanine-restricted diet.
  • Observed biochemical changes in blood were initially attributed to increased attention by medical staff, not the diet.

Key Insights:

  • Successful preparation of a phenylalanine-lowering formula was a critical step.

Related Experiment Videos

  • Demonstrated the feasibility of dietary intervention in managing PKU, even in later-diagnosed patients.
  • Highlighted the challenges in attributing treatment efficacy solely to diet versus supportive care in early case studies.

    • Outlook:

    • Paved the way for further research into PKU dietary therapies and their long-term effects.
    • Emphasized the importance of biochemical monitoring alongside clinical observation in metabolic disorders.
    • Underscored the need for robust evidence to support the benefits of novel treatments.